Shape the future of cervical cancer


screening: Identify HPV 31 Only an HPV test with extended genotyping can identify HPV 31 and track persistence for the most high-risk genotypes.*1-6


The BD Onclarity™ HPV Assay is the only FDA-approved assay with extended genotyping, positioning your laboratory at the forefront of cervical cancer screening, by enabling you to provide more actionable information to clinicians.5-10


Visit go.bd.com/onclarity to learn more about BD Onclarity™ HPV Assay and BD COR™ System


References: 1. Bonde J et al. Int J Cancer. 2019;145:1033-1041. 2. Elfgren K et al. AM J Obstet Gynecol. 2017;216(3):264e1-264.e7. 3. Radley D et al. Hum Vaccin Immunother. 2016;12(3):768-772. 4. Bodily J, Laimins LA. Trends Microbiol. 2011;19(1):33-39. 5. Stoler MH et al. Gynecol Oncol. 2019;153(1):26-33. 6. Bonde JH et al. J Low Genit Tract Dis. 2020;24(1):1-13. 7. Monsonego J et al. Gynecol Oncol. 2015;10:1016. 8. Schiff man M et al. Gynecol Oncol. 2015;138(3):573-578. 9. Schiff man M et al. Int J Cancer. 2016:139:2606-2615. 10. Schiff man M et al. J Clin Microbiol. 2015;53(1):52-59.


BD Life Sciences, Sparks, MD, 21152, USA 800.638.8663


BD, the BD Logo, BD COR, BD Onclarity and BD Viper are trademarks of Becton, Dickinson and Company or its affiliates. © 2021 BD. All rights reserved. (BD-36901 1317-US-1121 November 2021)


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50